QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-invivyd-raises-price-target-to-2

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:IVVD) with a Buy and raises the price target from $1 to $2.

 the-fda-clears-invivyds-investigational-new-drug-application-and-provided-feedback-to-advance-its-revolution--clinical-development-program-for-vyd2311-a-vaccine-alternative-monoclonal-antibody-candidate-to-prevent-covid-infection

The DECLARATION clinical trial is the company's Biologics License Application (BLA)-enabling, Phase 3 pivotal clinical tria...

 cantor-fitzgerald-initiates-coverage-on-invivyd-with-overweight-rating-announces-price-target-of-10

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Invivyd (NASDAQ:IVVD) with a Overweight rating and announces P...

 invivyd-filed-for-350m-mixed-shelf-offering

-SEC Filing

 steven-cohens-biotech-bets-are-getting-bolder--and-smaller

Billionaire hedge fund manager Steven Cohen is diving into small-cap biotech with new stakes in two clinical-stage companies, s...

 point72-hedge-fund-manager-steve-cohen-discloses-8-passive-stake-in-invivyd

-SEC Filing

 hc-wainwright--co-reiterates-buy-on-invivyd-maintains-5-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $5 price target.

 d-boral-capital-maintains-buy-on-invivyd-lowers-price-target-to-1

D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:IVVD) with a Buy and lowers the price target from $3 to $1.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION